Orforglipron vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Orforglipron is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Orforglipron | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | Limited community data available See research protocols | 120-240mg once daily (oral) Once daily |
| Administration | Oral tablet daily | Oral tablet |
| Typical Duration | Long-term use expected | 36 weeks in Phase 2 trials |
| Best Time to Take | Before bed or morning (fasted) | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026. FDA approved Foundayo (orforglipron) on April 1, 2026 under the National Priority Voucher Program - the fastest new molecular entity approval since 2002. It is the first oral non-peptide GLP-1 receptor agonist approved for chronic weight management. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Orforglipron vs Eloralintide
What is the difference between Orforglipron and Eloralintide?
Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. fda approved april 1, 2026 under the brand name foundayo - the first daily oral glp-1 pill for weight loss. distribution began april 6, 2026. fda subsequently requested additional post-approval safety data. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.